Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • JAK2 (Janus kinase 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
|
TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation
|
cyclophosphamide • ECT-001-CB